Cadila Health Care

8/7/2019 Cadila Health Care

1/23

Cadila Healthcare LtdHistory:Cadila Healthcare Ltd is a well known research-oriented, technology-driven

pharmaceutical company focused on the research areas of biotechnology, formulations

and Active Pharmaceutical Ingredients. They are an Indian based pharmaceutical

company having their presence around the world. They are having their manufacturingfacilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in

Maharashtra and Solan in Himachal Pradesh.

Cadila Healthcare Ltd, the flagship of Zydus Cadila Group was incorporated in May 1995

and they became a public limited company in July 1996. The company's operation

includes pharmaceuticals, which includes human formulations, veterinary formulationsand bulkdurgs, diagnostics, herbal products, skin care products and OTC products.

In the year 1996, the company made a strategic alliance with Gulin Pharma of China andlaunched Falcigo in India, which is an anti-malarial segment. In May 2000, the company

acquired formulation business of Recon Ltd, which strengthens the company in thesouthern market. In the year 2001, they acquired German Remedies which was the largest

M&A in the Indian Pharmaceutical sector and in the same year, they entered into a jointventure with US based Onconova for collaborative research in the field of

Oncogenomics.

In April 2002, the company acquired Banyan Chemicals, a Vadodara based company

with the US FDA approved plant. In the year 2003, German Remedies, Recon

Healthcare, Zoom Properties and Zydus Pathline merged with the company. Also, theyacquired Alpharma France, which spearheaded the group operations in France. In the

same year, the company emerged as a 'Partner of Choice' for Schering AG to manufacture

and market the products in India.

In November 2004, the company entered into a strategic alliance with Zambon Group in

Italy to open up new avenues in contract manufacturing. In the same year, the company

entered into a long term strategic pact with Boehringer Ingelheim India Ltd, a whollyowned subsidiary of Boerhringer Ingelheim (BI) to manufacture and market BI's products

in India.

In the year 2005, the company entered into a strategic alliance with Mallinckrodt

Pharmaceuticals Generics, a business unit of Tyco Healthcare to market the product

manufactured by the company under a joint label. In the same year, the company signed a

50:50 joint venture with Mayne Pharma of Australia to manufacture generic injectable,cytotoxic (anti-cancer) medicines as well as active pharmacetical ingredients (API) for

global markets.

During the year 2005-06, the company signed a 50:50 joint venture with one of India's

top biotech companies Bharat Serums and Vaccines Ltd (BSV) and formed Zydus BSV

Pharma Pvt Ltd to develop, manufacture and market non-infringing and proprietaryNovel Drug Delivery System (NDDS) of an approved anti-cancer product for global


2/23

markets.

During the year 2006-07, the company entered into share purchase agreement to acquire97.95% stake in Liva Healthcare Ltd, which is carrying on business of manufacturing and

marketing of Formulations. They established a green field facility for Solid Oral Dosage

Forms in Sikkim mainly for domestic market. They also installed Lyophilisation facilityat Moraiya plant with annual capacity of 7.5 million dosages to cater to both Indian and

International markets.

During the year 2007-08, the company restructured their formulation division namely

Alidac and launched two new sub division namely Corza and Fortiza. Also, they forayed

into the neutraceutical industry and launched a new division, Zydus Nutriva. The

upgradation of the injectibles facility at Moraiya was completed and also, they expandedtheir manufacturing facility at Ankleshwar.

Zydus Healthcare Brasil Ltd, Brazil, a wholly owned subsidiary of the company acquired

100% shareholding of Quimica e Farmaceutica Nikkho Do Brasil Ltda, a BrazilianPharmaceutical company to expand their branded business in Brazil. Also, Zydus

Pharmaceuticals Inc, Japan, a wholly owned subsidiary of the company acquired 100%shareholding in Nippon Universal Pharmaceuticals Co Ltd, Japanese Company, which is

carrying out business of manufacturing and marketing of pharmaceutical products in

Japan.

In February 2008, the company and Karo Bio of Sweden made a three year strategic

collaboration in the area of drug discovery and development. The company is in the

process of setting up a fine chemical facility at Dabhasa at a cost of about Rs 200 million,which will commence their production in the financial year 2008-09.

In May 2008, the company entered into Spain with the acquisition of 100% stake inLaboratories Combix. In June 2008, the company through their wholly owned subsidiary,

Zydus Healthcare SA Pty Ltd is acquiring majority state of 70% in Simayla

Pharmaceuticals of South Africa.

The company decided to demerge the Consumer Products Division of the company and

transferred to Carnation Nutra Analogue Foods Ltd, which is a subsidiary of Cadila

Healthcare and the merger of Zydus Hospital and Medical Research Pvt Ltd with thecompany.

In August 2008, the company has entered into an agreement with WHO to explore apossible collaboration in the development of a cocktail for the treatment of rabies,

through the use of monoclonal antibodies.

An Integrated Global Healthcare Company:Zydus Cadila is an innovative global pharmaceutical company that discovers, develops,

manufactures and markets a broad range of healthcare products. The groups operationsrange from API to formulations, animal health products and cosmeceuticals.


3/23

Headquartered in the city of Ahmedabad in India, the group has global operations in four

continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging

markets.

In its mission to create healthier communities globally, Zydus Cadila delivers wide

ranging healthcare solutions and value to its customers. With over 11,000 employeesworldwide, a world-class research and development centre dedicated to discovery

research and eight state-of-the-art manufacturing plants, the group is dedicated to

improving peoples lives.

About USA mission to create healthier communities

Zydus Cadila is dedicated to life

In all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern

for people in an effort to create healthier communities, globally.

A vision that unleashes value

To be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010;we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020.

Formulation business in India:With three multi-therapy divisions and eight specialty divisions, Zydus Cadila is one of the leading player in

the Indian healthcare industry. It is the leading player in the cardiovascular, gastrointestinal and women's

healthcare segments. The group has strong presence in respiratory, pain management, CNS, anti-infectives,

oncology, neurosciences, dermatology and nephrology segments. It has been able to maintain overall

position and market share through faster growing chronic / lifestyle segments. With several new product

introductions and pillar brands such as Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia, Mifegest to name

a few, Zydus Cadila is considered a tour-de-force in therapy management and brand management. The

group has several in-licensing alliances with global multinationals such as Schering AG, BoehringerIngelheim, Viatris, etc.

TA-wise break-up of formulations revenue

The portfolio of over 200 products are marketed by a specialised field force of 3,000. With one of the

strongest distribution channels in the industry, the group reaches out to 1,00,000 chemists and serves

2,00,000 doctors including physicians, specialists and super specialists.

Consumer Products Business - Zydus Wellness Ltd.

Apart from a strong presence in the prescription market, the group also caters to the growing

health and wellness segment through its subsidiary Zydus Wellness Ltd.

Zydus Wellness aims to promote healthy living by anticipating the emerging and day-to-day

needs in dietetic / health foods. Health and wellness have been identified as the emerging areas

in consumer healthcare. The Company is focussed on empowering individuals who wish to adopt

healthy eating habits and lifestyles.
http://void%280%29/http://void%280%29/


4/23

The Company is a pioneer, offering healthier dietary options to the consumers. The product range

comprisesSugar Free Gold Indias No.1 sweetener with a market share of over 70%, Sugar Free

Natura a zero calorie sucralose based sugar substitute, Sugar Free Dlite a low calorie healthy

drink and Nutralite a premium cholesterol-free table spread. Nutralite has emerged as the

second largest brand in the category of butter and butter substitutes.

The Company also caters to the skincare segment with its Everyuthand Dermacare brands,

which occupy a unique distinction of being a skincare brand from a healthcare company.

Enriched with the power of natural ingredients, EverYuth has a strong presence in advanced

skincare segments like soap-free, face washes, face masks, scrubs etc.

Formulation business in Global:

Zydus Cadila has strong global opetations to market both formulations and APIs. With operations

in U.S.A., Europe, Latin America, Japan and over 40 emerging markets across the world, Zydus

Cadila is a global healthcare provider. The group also manufactures and markets a wide range of

intermediates and APIs.

Manufacturing:A wide range of capabilities have helped the group create a robust manufacturing infrastructure. Spread

over five states of India, the group has eight state-of-the-art manufacturing facilities, creating a strong global

manufacturing hub for the group.

Proven strengths in formulationsmanufacturing
http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.nutralite.com/http://www.everyuth.com/http://www.everyuth.com/http://void%280%29/http://void%280%29/http://void%280%29/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.sugarfree-india.com/http://www.nutralite.com/http://www.everyuth.com/http://void%280%29/http://void%280%29/


5/23

Eight state-of-the-art plants

Four formulation plants - one each at Moraiya in Ahmedabad, Goa, Baddi and Sikkim Two API plants at Ankleshwar and Dabhasa. An Agiolax plant in Goa An API plant in Mumbai to manufacture key intermediates of Pantoprazole

Intermediates and APIs

Specialty chemicals, fine chemicals

Advanced intermediates

High end bulk actives

Investigational bulk actives

Formulations

Oral dosage forms (Tablets, hard and soft gel capsules)

Injectables (Sterile liquids and lyophilised)

Inhalers, transdermals, suppositories and vaccines

Formulation development for ANDA candidates at a dedicated Pharmaceutical Technology Centre

Development of specialised dosage forms

Key Factors:

Zydus Cadila is a global healthcare provider and one of the top five pharma companies in India.

The company was founded by Late Mr. Ramanbhai B. Patel in 1952 and went on to become the second

largest pharma company in the early 1990s.

In 1995, the group restructured its operations and now operates as Cadila Healthcare Ltd., under

the aegis of the Zydus group. The company spearheaded by Mr. Pankaj R. Patel, Chairman and Managing

Director posted a turnover of over Rs. 3700 crores in 2009-10.

The group has been listed as one of the Best Under a Billion company from amongst 200

companies in Asia by Forbes.

Proven expertise in manufacturing and marketing different dosage forms such as solid dosage

forms, injectables, metered dose inhalers, dry powder inhalers, transdermal patches, suppositories and

oncology formulations.

Wide therapy coverage through three multi-therapy divisions and eleven speciality divisions. The

divisions are spearheaded by some of the stalwarts in the field of pharma marketing.


6/23

A dedicated field force of 3300 reaches out to super specialists, specialists, surgeons, physicians

and the rural markets.

The group has a strong presence in the cardiovascular, gastrointestinal, womens healthcare

segments, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and

nephrology segments.

Leading the way through new product introductions, the group was the first to launch Nucoxia

(Etoricoxib), Nupatch (Diclofenac Patch), Pantodac (Pantoprazole), Mifegest (Mifepristone), Penegra

(Sildenafil Citrate), Providac Techsules, Betaferon, Fludara, Slimona (Rimonabant) and Novolizer in India.

The group has several brands that feature amongst the top 300 pharmaceutical brands in India.

The group has a globally compliant manufacturing infrastructure comprising eight state-of-the-art

facilities which support product launches not just in India but also in the regulated markets of U.S., Europe

and Latin America.

Three of the groups facilities including the formulation manufacturing plant at Moraiya, and API

plants at Ankleshwar and Dabhasa near Vadodara are approved by the USFDA.

More than 900 professionals spearhead the groups research programme.

Over 350 scientists are working on new molecular entity research at the Zydus Research Centre.

The group has eight INDs in various stages of clinical trials.

Zydus Cadila is a partner of choice for several global pharma majors such as Boehringer

Ingelheim, Bayer Schering Pharma, Madaus AG, Nycomed, Hospira, Bio Sidus of Argentina, Mallinckrodt

of USA, Abbott to name a few.

One of the most reputed pharma companies globally, Zydus Cadila aims to be a leading global

healthcare provider with a robust product pipeline and sales of over $1 billion by 2010. It plans to achieve

sales of over $3 billion by 2015 and be a global research-driven company by 2020.

Core value:


7/23

In the community:

In keeping with its mission to create healthier communities globally, Zydus Cadila is actively

involved in developing the community of which it forms a part.

Through the Ramanbhai Foundation, it has undertaken initiatives in the field of pharmaceutical

research, education and healthcare. Under the aegis of the Foundation, the group organises an

International Symposium on the latest trends in Pharmaceutical Sciences, once every two years.

Three International symposia have been held so far with more than 40 research scientists,academicians and research professionals from across the world sharing their insights on the

latest developments in pharmaceutical research.

The Zydus School for Excellence a centre for learning where young minds are free to grow in

relationship to his or her potential has also been set up under the aegis of the Foundation. The

Shri Ramanbhai Patel Memorial Scholarship Programme jointly funded by a grant from the

Ramanbhai Foundation and Zydus School for Excellence funds the education of students from


8/23

disadvantaged backgrounds.

Shri Ramanbhai B. Patel - AMA Centre for Excellence in Education, provides a platform for

parents, teachers and students to highlight the critical educational issues of the day. The centre

conducts open house discussions, memorial lectures on excellence in education, progressive

learning programmes for academicians and knowledge sharing forums. The centre also honoursteachers for their contributions to a childs world of learning.

Dedicated to the memory of the groups founder, the IPA Shri Ramanbhai B. Patel Foundation

(IRF) has been jointly set up with the Indian Pharmaceutical Association. IRF recognises and

honours commitment and excellence in the field of pharmacy.

As a part of its outreach programmes, the group organises rural healthcare camps annually with

its team of medical advisors and employees, volunteering their services. So far, the group has

organised general healthcare camps, diagnostic, dental-care, eye-care and paediatric camps.

The group has also initiated 'Project Unnati' for adolescent girls at Moraiya which focusses on

health and overall development.

Through the Ramanbhai Foundation, the group also extends its support during times of natural

calamities.

In recognition of its CSR initiatives, the group bagged the Social and Corporate Governance

Awards 2008 in the Best Social Responsibility Practice category presented by the BSE,

NASSCOM Foundation and Times Foundation

Research Focus:At Zydus Research Centre (ZRC), our focus is on finding innovative therapies for diseases affectingmankind through continuous research and development. The major areas of research includes:

New Molecular Entities Novel Drug Delivery Systems Therapeutic proteins and Vaccine by r-DNA technology Identification and validation of Therapeutic Targets

Scientific Advisory Board:

ZRC has constituted a Scientific Advisory Board comprising of world renowned scientists and clinicians to

advice the group in its research endeavors.

Dr. Richard DiMarchi

Dr. DiMarchi is presently a Professor of Chemistry and the Jack and Linda Gill Distinguished Chair in

Biomolecular Science at Indiana University. He currently serves as a co-founder and Board Chairman of

Ambrx Inc. Dr. DiMarchi was formerly Group Vice-President for Biotechnology and Product Development at

Lilly Research Laboratories, where he made major contributions to Lilly in biotechnology and endocrinology.

Dr. DiMarchi was directly involved in the discovery and development of several Lilly drugs, including

Humulin(R), Humatrope(R), Evista(R), Xigris(R), and Forteo(R). He was a co-inventor of Humalog(R), the

first biosynthetic protein approved for human use. ( For more details,click here)
http://void%280%29/http://void%280%29/http://void%280%29/


9/23

Dr. John Amatruda

Most recently Dr. Amatruda was Senior Vice President and Franchise Head for Diabetes and Obesity and a

member of the Research Management Committee at Merck. Dr Amatruda graduated from Yale University,

received his MD degree from the Medical College of Wisconsin and did his internship and residency in

Internal Medicine and Fellowship in Endocrinology and Metabolism at The Johns Hopkins Hospital. He is

board certified in internal medicine and Endocrinology and Metabolism. ( For more details,click here)

Suad Efendic, MD, PhD, Professor

Suad Efendic is a Professor of Endocrinology at Karolinska Institutet, Adjunct Professor of Physiology at the

University of Toronto, and Professor of Medicine at the University of Zagreb. Since 1991 he has been a

member of the Nobel prize Assembly. From 1988-1995 he was the Head of the Department of

Endocrinology and Diabetology at Karolinska Hospital. ( For more details,click here)

Dr. Lee S. Simon

Dr. Simon is currently an Associate Clinical Professor of Medicine at Harvard Medical School and Beth

Israel Deaconess Medical Center (BIDMC) in Boston, MA, USA. Previously, he was Director of

Rheumatology Clinical Research, an Associate Chief of Medicine, and Director of Graduate Medical

Education at BIDMC. ( For more details,click here)

Dr. Robert R. Henry

Dr. Henry is an internationally renowned clinical investigator and scientist. Dr. Henry is Professor of

Medicine at the University of California San Diego and the Chief of Endocrinology at the VA San Diego

Healthcare System. ( For more details,click here)

Dr. Charles F. Burant, MD, PhD

Dr. Charles F. Burant, MD, PhD is Professor of Internal Medicine at the University of Michigan Health

System in Ann Arbor, Michigan. He currently is the Robert C. and Veronica Atkins Professor of Metabolism

and directs the Michigan Metabolomics and Obesity Center. His research interests are in the areas of the

molecular and cellular biology of insulin resistance and the effect of insulin resistance on -cell function aswell as lipid and glucose metabolism. His clinical interests are focused on type 2 diabetes, insulin resistance,

and the metabolic syndrome. Dr Burant is an Associate Editor for the American Journal of Physiology-

Endocrinology and Metabolism. He is active in the American Diabetes Association, serving on the Research

Policy Committee and the Board of Directors of the Research Foundation.

( For more details,click here)

In addition to the Scientific Advisory Board, ZRC also has well-experienced advisors to help the

research team in making appropriate decisions on various targets and research areas of focus to the

company.

Dr. Walter WahliDr. Walter Wahli received his PhD in Bern in 1977. He carried out a post-doctoral fellowship with Dr. Igor

Dawid at the Department of Embryology, Carnegie Institution of Washington in Baltimore. He then was at

the Department of Biochemistry of the National Cancer Institute, NIH, in Bethesda, as visiting fellow and

visiting associate. He moved to Lausanne in 1980, where he was appointed Professor of biology and

Director of the Institute of animal biology of the University. He was Vice-Director for Research and

Postgraduate Education of the University between 1999 and 2003. In 2003, he became Director of the
http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/http://void%280%29/


10/23

Center for Integrative Genomics and in 2004 he was elected President of the Biology and Medicine Division

of the Swiss National Science Foundation.

The Otto Naegeli Award 2002 and the European Lipid Science Award 2002 have honored the work of Dr.Walter Wahli who has discovered novel nuclear hormone receptors, has identified specific ligands for thesereceptors, and has demonstrated the central physiological significance of these regulatory proteins in

metabolism, inflammation, and wound healing. Dr. Wahli has published many publications in well respectedand peer viewed journals and earned a respectable position in exploring mechanism of different diseasesrelated to nuclear receptors.

About ZRC:

Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus

Cadila, established in the year 2000. This state-of-the-art research centre, spread over an

area of 3,60,000 sq.ft., is located at Ahmedabad, in the western part of India. A team of

over 300 research scientists are actively engaged in research in various disciplines ofMedicinal Chemistry, Biotechnology, Cell Biology, Bioinformatics, Genomics,

Molecular Biology, Pharmacology, Toxicology, Microbiology, Analytical Research,

Clinical Research, Novel Process Research and Novel Drug Delivery Research.

Research Areas:Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus Cadila, established

in the year 2000.

At ZRC, research is mainly focussed on

NME research

Metabolic Disorders

Diabetes

Obesity

Dyslipidemia

Inflammation and Pain

Rheumatoid arthritis

Pain

Bacterial Infections

Biotechnology Research

Development of Biogeneric therapeutic proteins Development of Antibodies

Development of Vaccines

Search for Novel Targets

Validation of Targets

Chemical Manufacturing and Control


11/23

Development of Novel processes for NME's from Medicinal Chemistry

department

Chiral synthesis of drug and drug intermediates

Resolution of racemates

Studies in polymorphism of drug candidates Development of novel process of peptide drugs

Novel Drug Delivery Research

Research in delivery of proteins and peptides

Delivery of NME

R&D Organisation:

The R & D Organisation has capabilities to conduct Drug Discovery and Development fromconcept to IND enabling pre-clinical and clinical development.

Scientific Activities:

The Ramanbhai Foundation International Symposium is a biannual series of

symposia devoted to the discussion of new trends in the pharmaceutical industry with

a view to promoting scientific excellence in drug discovery and development.

Ramanbhai Foundation is named after a pathfinder, Late Mr. Ramanbhai B. Patel,

who had dedicated his life to the quest of knowledge, as an academician,

entrepreneur and a research scientist. He believed that new paths would surely open

up if one has the creative will to discover it. (To know more about Mr. Ramanbhai B.

Patel, Click here)The theme of the RBF

1st International

Symposium held in

the year 2003 was

'Current Trends in

Pharmaceutical

Sciences'. The

emphasis was on the

development of

therapeutic molecules

from mouse to man.

The theme of the

Ramanbhai

Foundation 2nd

International

Symposium was

'Current Trends in

Pharmaceutical
http://void%280%29/http://void%280%29/


12/23

Sciences' with an

emphasis on the role

of genomics and

proteomics research

in drug discovery and

development process.The symposium was held at ZRC from January 23-25, 2005.

The Ramanbhai Foundation 3rd International Symposium focused on Current Trends in

Pharmaceutical Sciences: Advances in diabetes therapy - Basic Science and Clinical Aspects.

The symposium was held at Zydus Research Centre, Ahmedabad from February 1-3, 2007.

The Ramanbhai Foundation 4th International Symposium was focussed on Advances in

Cardiometabolic Research and held from February 2-5, 2009, with focus on research in the area

of cardiovascular and metabolic diseases such as atherosclerosis, hypertension, heart failure,

diabetes and obesity.

To learn more about this biannual event and participate, please visit www.rbfsymposium.net

Discovery Pipeline:

New Molecular Entities in Development
http://www.rbfsymposium.net/http://www.rbfsymposium.net/


13/23

Biological Testing

Several NME's are under biological testing for treatment of arthritis, obesity and cardiovascular diseases.


14/23

Department of Biotechnology

Cloning, Fermentation and Purification of Therapeutic Proteins and Vaccines

Development of Animal Feed Supplement

Development of Diagnostic Kits

Patents

ZRC has filed over 108 patents in various therapeutic areas of NME research, Process Research, Novel

Process Research, Novel Drug Delivery and Biologicals, since its inception. Several of them have already

been granted US patents

Publications:


15/23

ZRC encourages scientists to publish their research findings in leading national and international journals.Some of the publications from

ZRC are listed below :

Bioisosteric replacement of Dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N-[(4-chlorophenyl)-

sulfonyl]-4-phenyl-4, 5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by

Imidazole and Oxazole.

Bioorg. Med. Chem. Lett. 2008, 18, 963

Convenient Synthesis of Structurally Novel 1,3-Disubstituted Azetidine Derivatives Synthetic

Communications, 2008, (accepted)

Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3-b]pyridines and thieno

[2,3-b]pyridines

Bioorganic and Medicinal Chemistry, 2007, 15 (21) , 6782-6795.

An improved synthesis of Fmoc-N-methyl serine and threonineTetrahedron Letters, 2007, 48 (29), 5003-5005

Synthesis and antidiabetic activity of 3,6,7-trisubstituted-2-(1H-imidazol- 2-ylsulfanyl)quinoxalines and

quinoxalin-2-yl isothioureas (2007)

Archiv der Pharmazie, 340 (7), pp. 359-366

Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin

secretagogues

Bioorganic and Medicinal Chemistry, 2007, 15 (17), 5950-5964

Design, Synthesis and biological evaluation of substituted N-(thieno[2,3-b]pyridin 3-yl)-guanidines, N-(1H-pyrrolo [2,3-b]pyridin-3-yl)-guanidines and N-(1H-indol-3yl)-guanidines.

Bioorganic and Medicinal Chemistry,2007, 15, 3248-65

Diaryl Dihydro pyrazole 3-carboxamides with significant in vivo antiobesity activity related to CB1

antagonisum: synthesis,Biological evaluation,and molecular modeling in the homology model.

Journal of Medicinal Chemistry, 2007, 50, 5951-5966

Synthesis and in vitro antibacterial activities of novel oxazolidinones Eur. J. Med. Chem. 2007, In Press,

Corrected Proof, Available online 27 May 2007 (doi:10.1016/j.ejmech.2007.05.003).

Synthesis and anti-bacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c] pyridine quinolones.

Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1924-1929

3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: A novel class of antibacterial

agents.

Bioorg. Med. Chem. Lett. 2006, 16, 3817


16/23

Novel Anti-infective Compounds

Pure Appl. Chem. 2005, 77, 195.

Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as anti-bacterials.

Bioorg. Med. Chem. Lett., 2006, 16: 1557-1561

Direct injection, column switchingliquid chromatographic technique for the estimation of rabeprazole in

bioequivalence study

Journal of Chromatography B, 2004, 813, 247254.

Novel tetrahydro-thieno pyridyl oxazolidinone: an anti-bacterial agent

Bioorganic & Medicinal Chemistry, 2004, 12, 4557-4564.

Novel Mannich ketones of oxazolidinones as anti-bacterial agents

European Journal of Medicinal Chemistry, 2004, 39, 989992.

Oxazolidinone: Search for highly potent antibacterial

Bioorganic & Medicinal Chemistry Letters, 2004, 14, 3139-3142.

Contributory patent infringement and the pharmaceutical industry

Journal of Intellectual Property Rights, 2003, 8, 302-311.

Collaborations:

Zydus Cadila is constantly seeking newer opportunities in:

Collaborative research and development In-licensing of technologies / NME's

Out-licensing / co-development of Zydus's drug candidates

For further details, please contact or submit your opportunities to:

Business DevelopmentZydus Research CentreSarkhej-Bavla N.H. No. 8AMoraiya, Ahmedabad - 382210Gujarat, IndiaPh: +91-2717-250801Fax: +91-2717-250606Email: [email protected]

Investor:It is our endeavour to provide the latest information for the benefit of the investing community. This section

also provides for downloading of various forms such as those for requesting change in address, transfer of

shares and for issuance of share certificates.

We welcome your suggestions and comments about the various features and facilities provided in this

section. We would also like to know from you other features or facilities that you would like us to provide in

this section.


17/23

Shareholding pattern for the quarter ended on 30th June, 2010

(I)(a) Statement showing Shareholding Pattern

Cate

-gory

Cod

e

(I)

Category of

shareholder

(II)

Number

ofshare-

holders

(III)

Total

number ofshares

(IV)

Number of

shares heldin de

materialized

form

(V)

Total Shareholding

as a percentage oftotal number of

shares

Shares pledged or

otherwise encumbered

As a

percenta

ge of

(A+B)

(VI)

As a

Percent-

tage of

(A+B+C)

(VII)

No. of

shares

(VIII)

As a

percentage

(IX) = (VIII)/

(IV)*100

(A) Shareholding of

Promoter and

Promoter Group

(1) Indian

(a) Individuals / Hindu

Undivided Family

(incl. a Family

Trust)

10 153134446153134446 74.79 74.79

(b) Central

Government /

State

Government(s)

Nil - - - -

(c) Bodies Corporate 1 3600 3600 - -

(d) Financial

Institutions /

Banks

Nil - - - -

(e) Any Other

(Specify)

Nil - - - -

(Sub-Total (A)(1) 11 153138046153138046 74.79 74.79 Nil

(2) Foreign

(a) Individuals (Non-

Resident

Individuals /

Foreign

Nil - - - -


18/23

Individuals)

(b) Bodies Corporate Nil - - - -

(c) Institutions Nil - - - -

(d) Any Other

(specify)

Nil - - - -

(Sub-Total (A)(2) Nil - - - - Nil -

Total

Shareholding of

Promoter and

Promoter Group

(A) = (A)(1)+(A)

(2)

11 153138046153138046 74.79 74.79 Nil -

(B) Public

Shareholding

N.A. N.A.

(1) Institutions N.A. N.A.

(a) Mutual Funds /

UTI

65 14265900 14262366 6.97 6.97

(b) Financial

Institutions /

Banks

14 6476 4799 0 0

(c) CentralGovernment /

State

Government(s)

Nil - - - -

(d) Venture Capital

Funds

Nil - - - -

(e) Insurance

Companies

10 12568878 12568878 6.14 6.14

(f) Foreign

InstitutionalInvestors

62 9095389 9095014 4.44 4.44

(g) Foreign Venture

Capital Investors

Nil - - - -

(h) Any Other

(Specify)

Nil - - - -


19/23

Sub-Total (B)(1) 151 35936643 35931057 17.55 17.55

(2) Non-Institutions

(a) Bodies Corporate 702 2266849 2261923 1.11 1.11

(b) Individuals -

1. Individual

Shareholde

rs holding

nominal

share

capital up

to Rs.1

lakh.

2. Individualshareholde

rs holding

nominal

share

capital in

excess of

Rs.1 lakh.

37846

14

*9060146

1545484

7301612

1491604

4.42

0.76

4.42

0.76

(c) Any Other

(specify) NRI/OCB

606 2801352 2781780 1.37 1.37 N.A. N.A.

Sub-Total (B)(2) 39168 15673831 13836919 7.66 7.66 N.A. N.A.

Total Public

shareholding

(B) = (B)(1)+(B)

(2)

39319 51610474 49767976 25.21 25.21 N.A. N.A.

TOTAL (A)+(B) 39330 204748520 202906022 100.00 100.00

(C) Shares held by

Custodians and

against which

Depository

Receipts have

been issued

GRAND TOTAL

(A)+(B)+(C)

Nil - - - - N.A. N.A.

GRAND

TOTAL(A)+(B)+

39330 204748520 202906022 100.00 100.00 N.A. N.A.


20/23

(C)

* Including 29453 shares in transit.

(I)(b) Statement showing Shareholding of persons belonging to the category "Promoter

and Promoter Group"

Sr.

No.

(I)

Name of the

Shareholder

(II)

Total shares held Shares pledged or otherwise encumbered

Number of

Shares

(III)

Shares as a

percentage of

total number of

shares {i.e.,

Grand Total

(A)+(B)+(C)indicated in

Statement at

Para (I)(a)

above}

(IV)

Number

(V)

As a percent-

tage

(VI)= (V)/

(III)*100

As a % of

grand total (A)+

(B)+(C) of sub-

clause (I)(a)

(VII)

1. ZYDUS FAMILY

TRUST

153107446 74.78 Nil N.A. -

2. PRIPAN

INVESTMENT

PVT. LTD.

3600 0.002 Nil N.A. -

3. SHIVANI

PANKAJBHAI

PATEL JTLY.

PANKAJBHAI

RAMANBHAI

PATEL

3000 0.002 Nil N.A. -

4. PANKAJBHAI

RAMANBHAI PTEL

JTLY.

PRITIBENPANKAJBHAI

PATEL

3000 0.002 Nil N.A. -

5. PANKAJBHAI

RAMANBHAI

PATEL (HUF)

3000 0.002 Nil N.A. -


21/23

6. PRITIBEN

PANKAJBHAI

PATEL JTLY.

PANKAJBHAI

RAMANBHAI

PATEL

3000 0.002 Nil N.A. -

7. TARABEN

RAMANBHAI

PATEL JTLY.

PANKAJBHAI

RAMANBHAI

PATEL

3000 0.002 Nil N.A. -

8. RAMANBHAI B.

PATEL (HUF)

3000 0.002 Nil N.A. -

9. PANKAJBHAIRAMANBHAI

PATEL JTLY.

PRITIBEN

PANKAJBHAI

PATEL

(R. B. PATEL WILL

PANKAJ TRUST)

3000 0.002 Nil N.A. -

10. PANKAJBHAI

RAMANBHAI

PATEL JTLY.

SHARVIL

PANKAJBHAI

PATEL

(P. R. PATEL

SMALLER HUF)

3000 0.002 Nil N.A. -

11. SHARVIL

PANKAJBHAI

PATEL

3000 0.002 Nil N.A. -

TOTAL 153138046 74.79 Nil N.A. -

(I)(c) Statement showing Shareholding of persons belonging to the category "Public"

and holding more than 1% of the total number of shares

Sr.

No.

Name of the Shareholder Number of

Shares

Shares as a percentage of total number

of shares {i.e., Grand Total (A)+(B)+(C)


22/23

indicated in Statement at Para (I)(a)

above}

1. LIFE INSURANCE COPRORATION OF

INDIA

8085210 3.95

2. DALI LIMITED 2512327 1.23

TOTAL 10597537 5.18

(I)(d) Statement showing details of locked-in shares Not Applicable

Sr.

No.

Name of the Shareholder Number of

locked-in

Shares

Locked-in shares as a percentage of

total number of shares {i.e., Grand Total

(A)+(B)+(C) indicated in Statement at

Para (I)(a) above}

1. Zydus Family Trust (Promoter Group)@ 25221326 12.32

TOTAL 25221326 12.32

@ Lock-in till 05.03.2012

(II)(a) Statement showing details of Depository Receipts (DRs) Not Applicable

Sr.

No.

Type of outstanding DR

(ADRs, GDRs, SDRs,

etc.)

Number of outstanding

DRs

Number of shares

underlying

outstanding DRs

Shares underlying

outstanding DRs as a

percentage of total numberof shares {i.e., Grand Total

(A)+(B)+(C) indicated in

Statement at Para (I)(a)

above}

TOTAL Nil - -

(II)(b) Statement showing Holding of Depository Receipts (DRs), where underlying

shares are in excess of 1% of the total number of shares. Not applicable

Sr.

No.

Name of the DR Holder Type of outstanding DR

(ADRs, GDRs, SDRs,

etc.)

Number of shares

underlying

outstanding DRs

Shares underlying

outstanding DRs as a

percentage of total number

of shares {i.e., Grand Total

(A)+(B)+(C) indicated in


23/23

Statement at Para (I)(a)

above}

TOTAL Nil -

Cadila Health Care

Documents

Transcript of Cadila Health Care